Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEMBRO-RT: Pembrolizumab with or without SBRT in advanced non-small cell lung cancer
2014-005118-49Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Overall response rate at 12 weeks. Started Nov 2015; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-005118-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005118-49.